Literature DB >> 12796360

Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.

Linda J Patrick-Miller1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12796360

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  3 in total

Review 1.  Chemotherapy research for metastatic prostate cancer.

Authors:  Anil Kapoor; Sebastien J Hotte
Journal:  Can Urol Assoc J       Date:  2016-08       Impact factor: 1.862

Review 2.  A review of the application, feasibility, and the psychometric properties of the individualized measures in cancer.

Authors:  Ala' S Aburub; Nancy E Mayo
Journal:  Qual Life Res       Date:  2016-11-18       Impact factor: 4.147

3.  A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.

Authors:  Robert S DiPaola; Yu-Hui Chen; Mark Stein; David Vaughn; Linda Patrick-Miller; Michael Carducci; Bruce Roth; Eileen White; George Wilding
Journal:  J Transl Med       Date:  2010-02-24       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.